<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735290</url>
  </required_header>
  <id_info>
    <org_study_id>IM-202</org_study_id>
    <nct_id>NCT03735290</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer</brief_title>
  <acronym>ILIAD</acronym>
  <official_title>A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunicum AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunicum AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing&#xD;
      dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor&#xD;
      (CPI) pembrolizumab. The Phase 1b study will determine the optimal dose and schedule of&#xD;
      ilixadencel. Patients in the Phase 2 part of the study will be randomly assigned to receive&#xD;
      either ilixadencel (at the dose determined in Phase 1b) combined with the CPI, or only the&#xD;
      CPI.&#xD;
&#xD;
      Note: Recruitment to Phase 1b of the study has been completed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improvements achieved with the use of CPIs, 50-80% of cancer patients do not respond&#xD;
      to this therapy. There is growing evidence that combining CPIs with other forms of&#xD;
      immunotherapy has the potential to improve the desired effects of both CPIs and&#xD;
      immunotherapies. This study looks at the safety and effectiveness of the immunotherapy&#xD;
      ilixadencel when used in combination with a CPI. A Dose-escalation Committee (DEC) will&#xD;
      monitor the study for any significant safety issues during Phase 1b.&#xD;
&#xD;
      Note: Recruitment to Phase 1b of the study has been completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single arm phase 1b. Randomized phase 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs) (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events (SAEs) (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs) (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Dose Limiting Toxicities measured using CTCAE v5.0 and protocol DLT definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant laboratory test abnormalities (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with vital sign abnormalities (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Vital signs grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor Objective Response Rate (ORR) (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, centrally assessed using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor Objective Response Rate (ORR) RECIST 1.1 (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, investigator and centrally assessed using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Objective Response Rate (ORR) iRECIST (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, investigator assessed using iRECIST (Immune Response Evaluation Criteria in Solid Tumors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Rate of complete and partial response and stable disease by investigator and centrally assessed RECIST (Response Evaluation Criteria in Solid Tumors) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 24 months after Cycle 1 Day 1</time_frame>
    <description>Measured in weeks. Assessed using RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 24 months after Cycle 1 Day 1</time_frame>
    <description>Measured in weeks. Assessed using RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 24 months after Cycle 1 Day 1</time_frame>
    <description>Measured in weeks. Centrally assessed using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measured in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AEs) (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events (AEs) (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs) (Phase 2)</measure>
    <time_frame>Up to week 27</time_frame>
    <description>Dose Limiting Toxicities measured using CTCAE v5.0 and protocol DLT definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant laboratory test abnormalities (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with vital sign abnormalities (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Vital signs grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 1, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 2, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 3, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 4, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ilixadencel</intervention_name>
    <description>Intra-tumoral injection</description>
    <arm_group_label>Phase 1b: Cohort 1, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 2, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 3, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 4, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg</description>
    <arm_group_label>Phase 1b: Cohort 1, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 2, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 3, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 4, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
    <arm_group_label>Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must provide written informed consent.&#xD;
&#xD;
          -  Must have histologically confirmed and specific (Human Papilloma Virus) HPV-positive&#xD;
             or HPV-negative squamous cell carcinoma of the head and neck (SCCHN), non-small-cell&#xD;
             lung cancer (NSCLC) or gastric or gastroesophageal junction (GEJ) adenocarcinoma.&#xD;
             Patients with other tumor types who are candidates for pembrolizumab therapy&#xD;
             (according to the FDA-approved prescribing information at the time of inclusion) can&#xD;
             also be enrolled in Phase 1b. Tumor histology and most recent pathology report must be&#xD;
             in subject's medical record. Tumor samples and/or biopsies will not be collected as&#xD;
             part of this study.&#xD;
&#xD;
          -  Eligible for pembrolizumab treatment per country-specific label and per physician's&#xD;
             decision.&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Women of childbearing potential must follow contraceptive requirements; must have a&#xD;
             negative pregnancy blood test at screening, and a negative blood or urine pregnancy&#xD;
             test within 24 hours before each dose of ilixadencel; and must not be breastfeeding.&#xD;
&#xD;
          -  Male subjects must agree to use condoms from screening until 90 days after the last&#xD;
             dose of ilixadencel, or must have a female partner using a highly effective method of&#xD;
             contraception as described above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of invasive malignancy, unless complete remission has been achieved for&#xD;
             at least 3 years and no additional therapy is required except for hormonal therapy or&#xD;
             bisphosphonates.&#xD;
&#xD;
          -  Active or previously untreated brain and/or leptomeningeal metastasis.&#xD;
&#xD;
          -  Active autoimmune disease, pneumonitis or interstitial lung disease.&#xD;
&#xD;
          -  Certain heart conditions including, but not limited to: Congestive heart failure;&#xD;
             uncontrolled hypertension; unstable angina pectoris; pericarditis; myocarditis;&#xD;
             mycardial infarction 6 months prior to study.&#xD;
&#xD;
          -  Systemic immunosuppression except for replacement therapy.&#xD;
&#xD;
          -  Life expectancy of less than 3 months.&#xD;
&#xD;
          -  Any prior treatment with ilixadencel or prior treatment with anticancer agents (except&#xD;
             pembrolizumab or other CPI for subjects in Phase 1b) within 4 weeks of starting study&#xD;
             medication.&#xD;
&#xD;
          -  Major surgery or significant traumatic injury within 4 weeks before study start.&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Active tuberculosis; active infection requiring anti-infective therapy (hepatitis with&#xD;
             a negative viral load on maintenance will not be excluded).&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria could apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Domeij</last_name>
    <role>Study Director</role>
    <affiliation>Immunicum AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1010</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1006</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1011</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1004</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1009</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>ilixadencel</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>allogeneic</keyword>
  <keyword>somatic cell therapy</keyword>
  <keyword>dendritic cell</keyword>
  <keyword>intratumoral</keyword>
  <keyword>in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

